Loading
Every dated change on the records linked to Diffuse midline glioma, H3 K27-altered (including DIPG), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Dordaviprone (ONC201), FDA accelerated approval August 2025 for patients aged one year and older with progressive disease; re-irradiation is an alternative or addition.
FDA accelerated approval on 6 August 2025 for progressive H3 K27M-mutant diffuse midline glioma, the first systemic therapy for the disease.
Actionable alteration in 31.
Majzner and colleagues (Nature) report clinical and radiographic improvement with intravenous then intracerebroventricular dosing.